ERBB2 and neoplasm: The remaining 5 patients with undetectable HER2 variants were categorized as nonshedding tumor, with a trend of higher ORR (60.0% vs 24.4%, p = 0.126) and longer PFS (median: 10.2 vs. 6.8 months, p = 0.131), though not reaching statistical difference due to small sample size of nonshedding tumor.